Biomarkers in renal cell carcinoma: A metabolomics approach

Metabolomics

Volumn 10, Issue 6, 2014, Pages 1210-1222

  Monteiro, Márcia Sá ^a   Carvalho, Márcia ^a,b   de Lourdes Bastos, Maria ^a   de Pinho, Paula Guedes ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Biomarker discovery; Metabolic signature; Metabolomics; Renal cell carcinoma

Indexed keywords

EID: 84939881775     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-014-0659-5     Document Type: Article

References (78)

1. Abaffy, T., Moller, M., et al. (2011). A case report - Volatile metabolomic signature of malignant melanoma using matching skin as a control. Journal of Cancer Science and Therapy,3(6), 140–144.
2. Abaffy, T., Möller, M. G., et al. (2013). Comparative analysis of volatile metabolomics signals from melanoma and benign skin: A pilot study. Metabolomics,9, 1–11.
3. Algaba, F., Akaza, H., et al. (2011). Current Pathology Keys of Renal Cell Carcinoma. European Urology,60(4), 634–643.
4. Ather, M. H., Masood, N., et al. (2010). Current management of advanced and metastatic renal cell carcinoma. Urology Journal,7(1), 1–9.
5. Basso, M., Cassano, A., et al. (2010). A survey of therapy for advanced renal cell carcinoma. Urologic Oncology,28(2), 121–133.
6. Bouatra, S., Aziat, F., et al. (2013). The human urine metabolome. PLoS ONE,8(9), e73076.
7. Brahimi-Horn, M. C., Bellot, G., et al. (2011). Hypoxia and energetic tumour metabolism. Current Opinion in Genetics & Development,21(1), 67–72.
8. Cairns, P. (2010). Renal cell carcinoma. Cancer Biomarkers,9(1–6), 461–473.
9. Cantor, J. R., & Sabatini, D. M. (2012). Cancer cell metabolism: one hallmark, many faces. Cancer Discovery,2(10), 881–898.
10. Cardaci, S., & Ciriolo, M. R. (2012). TCA cycle defects and cancer: When metabolism tunes redox State. International Journal of Cell Biology,2012, 9.
11. Catchpole, G., Platzer, A., et al. (2011). Metabolic profiling reveals key metabolic features of renal cell carcinoma. Journal of Cellular and Molecular Medicine,15(1), 109–118.
12. Cerella, C., Radogna, F., et al. (2013). Natural compounds as regulators of the cancer cell metabolism. International Journal of Cell Biology,2013, 16.
13. Christians, U., Albuisson, J., et al. (2011). Chapter 3—the role of metabolomics in the study of kidney diseases and in the development of diagnostic tools. In L. E. Charles & C. L. Edelstein (Eds.), Biomarkers in kidney disease (pp. 39–100). San Diego: Academic Press.
14. Cohen, H. T., & McGovern, F. J. (2005). Renal-cell carcinoma. The New England Journal of Medicine,353(23), 2477–2490.
15. Dang, C. V. (2010). Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells? Cell Cycle,9(19), 3884–3886.
16. Dang, C. V. (2012). Links between metabolism and cancer. Genes & Development,26(9), 877–890.
17. Davis, V. W., Bathe, O. F., et al. (2011). Metabolomics and surgical oncology: Potential role for small molecule biomarkers. Journal of Surgical Oncology,103(5), 451–459.
18. DeBerardinis, R. J., Lum, J. J., et al. (2008a). The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism,7(1), 11–20.
19. Deberardinis, R. J., Sayed, N., et al. (2008b). Brick by brick: Metabolism and tumor cell growth. Current Opinion in Genetics & Development,18(1), 54–61.
20. Denkert, C., Budczies, J., et al. (2006). Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Research,66(22), 10795–10804.
21. Di Napoli, A., & Signoretti, S. (2009). Tissue biomarkers in renal cell carcinoma: Issues and solutions. Cancer,115(10 Suppl), 2290–2297.
22. Drabkin, H. A., & Gemmill, R. M. (2012). Cholesterol and the development of clear-cell renal carcinoma. Current Opinion in Pharmacology,12(6), 742–750.
23. Fiehn, O. (2002). Metabolomics–the link between genotypes and phenotypes. Plant Molecular Biology,48(1–2), 155–171.
24. Ganti, S., Taylor, S. L., et al. (2012a). Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Research,72(14), 3471–3479.
25. Ganti, S., Taylor, S. L., et al. (2012b). Urinary acylcarnitines are altered in human kidney cancer. International Journal of Cancer,130(12), 2791–2800.
26. Ganti, S., & Weiss, R. H. (2011). Urine metabolomics for kidney cancer detection and biomarker discovery. Urologic Oncology,29(5), 551–557.
27. Gao, H., Dong, B., et al. (2008). Metabonomic profiling of renal cell carcinoma: High-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Analytica Chimica Acta,624(2), 269–277.
28. Gao, H., Dong, B., et al. (2012). Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. Journal of Cancer Research and Clinical Oncology,138(5), 753–761.
29. Gatenby, R. A., & Gillies, R. J. (2008). A microenvironmental model of carcinogenesis. Nature Reviews Cancer,8(1), 56–61.
30. German, J. B., Hammock, B. D., et al. (2005). Metabolomics: building on a century of biochemistry to guide human health. Metabolomics,1(1), 3–9.
31. Gillies, R., & Gatenby, R. (2007a). Adaptive landscapes and emergent phenotypes: Why do cancers have high glycolysis? Journal of Bioenergetics and Biomembranes,39(3), 251–257.
32. Gillies, R., & Gatenby, R. (2007b). Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer and Metastasis Reviews,26(2), 311–317.
33. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell,144(5), 646–674.
34. Hsu, P. P., & Sabatini, D. M. (2008). Cancer cell metabolism: Warburg and beyond. Cell,134(5), 703–707.
35. Jonasch, E., Futreal, P. A., et al. (2012). State of the science: An update on renal cell carcinoma. Molecular Cancer Research,10(7), 859–880.
36. Jones, R. G., & Thompson, C. B. (2009). Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes & Development,23(5), 537–548.
37. Kaelin, W. G, Jr. (2004). The von Hippel–Lindau tumor suppressor gene and kidney cancer. Clinical Cancer Research,10(18 Pt 2), 6290S–6295S.
38. Kim, K., Aronov, P., et al. (2009). Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Molecular and cellular proteomics,8(3), 558–570.
39. Kim, D. S., Choi, Y. P., et al. (2010). Panel of candidate biomarkers for renal cell carcinoma. Journal of Proteome Research,9(7), 3710–3719.
40. Kim, K., Taylor, S. L., et al. (2011). Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS: A Journal of Integrative Biology,15(5), 293–303.
41. Kind, T., Tolstikov, V., et al. (2007). A comprehensive urinary metabolomic approach for identifying kidney cancerr. Analytical Biochemistry,363(2), 185–195.
42. Kominsky, D. J., Klawitter, J., et al. (2009). Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clinical Cancer Research,15(10), 3442–3450.
43. Kroemer, G., & Pouyssegur, J. (2008). Tumor cell metabolism: Cancer’s Achilles’ Heel. Cancer cell,13(6), 472–482.
44. Lin, L., Huang, Z., et al. (2011). LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. Journal of Proteome Research,10(3), 1396–1405.
45. Lin, L., Yu, Q., et al. (2010). Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. Analyst,135(11), 2970–2978.
46. Linehan, W. M., Srinivasan, R., et al. (2010). The genetic basis of kidney cancer: A metabolic disease. Nat Rev Urol,7(5), 277–285.
47. Ljungberg, B., Cowan, N., et al. (2010a). Guidelines on renal cell carcinoma. Arnhem: European Association of Urology.
48. Ljungberg, B., Cowan, N. C., et al. (2010b). EAU guidelines on renal cell carcinoma: The 2010 update. European Urology,58(3), 398–406.
49. Moch, H. (2013). An overview of renal cell cancer: Pathology and genetics. Seminars in Cancer Biology,23(1), 3–9.
50. Monteiro, M. S., Carvalho, M., et al. (2013). Metabolomics analysis for biomarker discovery: advances and challenges. Current Medicinal Chemistry,20(2), 257–271.
51. Mullen, A. R., Wheaton, W. W., et al. (2012). Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature,481(7381), 385–388.
52. Nicholson, J. K., & Lindon, J. C. (2008). Systems biology: Metabonomics. Nature,455(7216), 1054–1056.
53. Odunsi, K., Wollman, R. M., et al. (2005). Detection of epithelial ovarian cancer using 1H NMR-based metabonomics. International Journal of Cancer,113(5), 782–788.
54. Oosterwijk, E., Rathmell, W. K., et al. (2011). Basic research in kidney cancer. European Urology,60(4), 622–633.
55. Perroud, B., Lee, J., et al. (2006). Pathway analysis of kidney cancer using proteomics and metabolic profiling. Molecular Cancer,5, 64.
56. Pinthus, J. H., Whelan, K. F., et al. (2011). Metabolic features of clear-cell renal cell carcinoma: Mechanisms and clinical implications. Canadian Urological Association Journal,5(4), 274–282.
57. Rasmussen, L., Savorani, F., et al. (2011). Standardization of factors that influence human urine metabolomics. Metabolomics,7(1), 71–83.
58. Ros, S., & Schulze, A. (2012). Linking glycogen and senescence in cancer cells. Cell Metabolism,16(6), 687–688.
59. Saude, E., Adamko, D., et al. (2007). Variation of metabolites in normal human urine. Metabolomics,3(4), 439–451.
60. Saude, E., & Sykes, B. (2007). Urine stability for metabolomic studies: effects of preparation and storage. Metabolomics,3(1), 19–27.
61. Seliger, B., Dressler, S. P., et al. (2007). Candidate biomarkers in renal cell carcinoma. Proteomics,7(24), 4601–4612.
62. Seliger, B., Dressler, S. P., et al. (2009). Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics,9(6), 1567–1581.
63. Seliger, B., Lichtenfels, R., et al. (2005). Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics,5(10), 2631–2640.
64. Semenza, G. L. (2002). HIF-1 and tumor progression: pathophysiology and therapeutics. Trends in Molecular Medicine,8(4), S62–S67.
65. Serkova, N. J., Spratlin, J. L., et al. (2007). NMR-based metabolomics: translational application and treatment of cancer. Current Opinion in Molecular Therapeutics,9(6), 572–585. [ABSTRACT].
66. Shaw, R. J. (2006). Glucose metabolism and cancer. Current Opinion in Cell Biology,18(6), 598–608.
67. Spratlin, J. L., Serkova, N. J., et al. (2009). Clinical applications of metabolomics in oncology: A review. Clinical Cancer Research,15(2), 431–440.
68. Sudarshan, S., Karam, J. A., et al. (2013). Metabolism of kidney cancer: From the lab to clinical practice. European Urology,63(2), 244–251.
69. Teratani, T., Domoto, T., et al. (2007). Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology,69(2), 236–240.
70. Vasudev, N. S., & Banks, R. E. (2011). Chapter 8—biomarkers of renal cancer. In L. E. Charles & L. C. Edelstein (Eds.), Biomarkers in kidney disease (pp. 313–350). San Diego: Academic Press.
71. Vermeersch, K. A., & Styczynski, M. P. (2013). Applications of metabolomics in cancer research. Journal of Carcinogenesis,12, 9.
72. Walsh, M. C., Brennan, L., et al. (2006). Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. The American Journal of Clinical Nutrition,84(3), 531–539.
73. Warburg, O. (1956). On the origin of cancer cells. Science,123(3191), 309–314.
74. Weiss, R. H., & Kim, K. (2012). Metabolomics in the study of kidney diseases. Nature Reviews. Nephrology,8(1), 22–33.
75. Yang, J., Xu, G., et al. (2004). Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. Journal of Chromatography B,813(1–2), 59–65.
76. Zhang, A., Sun, H., et al. (2012a). Recent and potential developments of biofluid analyses in metabolomics. Journal of Proteomics,75(4), 1079–1088.
77. Zhang, A., Sun, H., et al. (2012b). Urine metabolomics. Clinica Chimica Acta,414C, 65–69.
78. Zira, A. N., Theocharis, S. E., et al. (2010). 1H NMR Metabonomic Analysis in Renal Cell Carcinoma: A Possible Diagnostic Tool. Journal of Proteome Research,9(8), 4038–4044.